

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	4	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	5	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	6	FEB 10	COMPENDEX reloaded and enhanced
NEWS	7	FEB 11	WTEXTILES reloaded and enhanced
NEWS	8	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	9	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	10	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	11	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	12	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	13	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	14	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	15	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	16	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	17	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	18	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS	19	MAR 23	CA/CAPLUS enhanced with more than 250,000 patent equivalents from China
NEWS	20	MAR 30	IMSPATENTS reloaded and enhanced
NEWS	21	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS	22	APR 07	STN is raising the limits on saved answers
NEWS	23	APR 24	CA/CAPLUS now has more comprehensive patent assignee information
NEWS	24	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS	25	APR 28	CAS patent authority coverage expanded
NEWS	26	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS	27	APR 28	Limits doubled for structure searching in CAS REGISTRY

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:08:52 ON 04 MAY 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 15:08:59 ON 04 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 MAY 2009 HIGHEST RN 1141929-94-3
DICTIONARY FILE UPDATES: 3 MAY 2009 HIGHEST RN 1141929-94-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10587682.str



```

chain nodes :
11 12 14 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 15 16 17 18 19 20
chain bonds :
1-14 6-11 9-12 10-21 14-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 15-16 15-20 16-17 17-18
18-19 19-20
exact/norm bonds :
1-2 1-6 1-14 2-3 3-4 4-5 4-7 5-6 5-10 6-11 7-8 8-9 9-10 9-12 10-21
exact bonds :
14-15
normalized bonds :
15-16 15-20 16-17 17-18 18-19 19-20
isolated ring systems :
containing 1 : 15 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom
21:CLASS

```

L1 STRUCTURE UPLOADED

```

=> d l1
L1 HAS NO ANSWERS
L1        STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

```

Structure attributes must be viewed using STN Express query preparation.

```

=> s l1 full
FULL SEARCH INITIATED 15:09:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        932 TO ITERATE

```

```

100.0% PROCESSED        932 ITERATIONS        177 ANSWERS
SEARCH TIME: 00.00.01

```

L2 177 SEA SSS FUL L1

```

=> file caplus
COST IN U.S. DOLLARS                    SINCE FILE        TOTAL
                                         ENTRY        SESSION
FULL ESTIMATED COST                    185.88        186.10

```

```

FILE 'CAPLUS' ENTERED AT 15:09:22 ON 04 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 May 2009 VOL 150 ISS 19
FILE LAST UPDATED: 3 May 2009 (20090503/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2 full
L3 7 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1367982 CAPLUS

DOCUMENT NUMBER: 149:556676

TITLE: Synthesis of diazocino[2,1-a]naphthyridinetriene derivative in crystalline form

INVENTOR(S): Lohani, Sachin; Peng, Zhihui; Mckeown, Arlene E.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 36pp.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080280945	A1	20081113	US 2008-151744	20080508
PRIORITY APPLN. INFO.: GI			US 2007-928292P P	20070509



AB Crystalline forms of a hexahydro-diazocinonaphthyridine trione I are disclosed. The compound and its crystalline forms thereof are HIV integrase inhibitors useful for the prophylaxis or treatment of HIV infection or for the prophylaxis, treatment or delay in the onset or progression of AIDS (data not shown).


IT 865300-81-8P 865300-86-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diazocinonaphthyridinetriene in crystalline forms for pharmaceutical use)


RN 865300-81-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid,
6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)



RN 865300-86-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid,
6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-
dioxo-, ethyl ester (CA INDEX NAME)




ACCESSION NUMBER:	2008:1298436	CAPLUS
DOCUMENT NUMBER:	150:47221	
TITLE:	Serendipitous discovery of a pH-dependent atropisomer bond rotation: Toward a write-protectable chiral molecular switch?	
AUTHOR(S):	Welch, Christopher J.; Biba, Mirlinda; Pye, Philip; Angelaud, Remy; Egbertson, Melissa	
CORPORATE SOURCE:	Department of Process Research, Merck Research Laboratories, Inc., Rahway, NJ, 07065, USA	
SOURCE:	Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2008), 875(1), 118-121	
	CODEN: JCBAAI; ISSN: 1570-0232	
PUBLISHER:	Elsevier B.V.	
DOCUMENT TYPE:	Journal	
LANGUAGE:	English	

AB Owing to slow rotation of a sterically constrained dimethylamide substituent, two slowly interconverting enantiomers of a preclin. candidate for pharmaceutical development, 1, (6-(3-Chloro-4-fluoro-benzyl)-4-hydroxy-2-methyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-[2,6]naphthyridine-1-carboxylic acid dimethylamide) are observed by chiral chromatog. Isolation of pure enantiomer by preparative chiral chromatog. followed by enantiopurity anal. over time allowed for a study of the kinetics of enantiomer interconversion under a variety of conditions. Relatively slow racemization was observed in alc. solvents, with a half life on the order of 5-10 h. A dramatic influence of aqueous buffer pH on racemization was noted, with higher pH leading to rapid racemization within a few minutes, and lower pH leading to essentially no racemization for periods up to a week. A hypothesis explaining this unusual effect of pH on carboxamide bond rotation is offered, and some suggestions for potential utility of such a system are considered.

IT 865298-81-3
RL: ANT (Analyte); PEP (Physical, engineering or chemical process); PRP (Properties); ANST (Analytical study); PROC (Process)
(pH-dependent atropisomer bond rotation and potential use as chiral mol. switch)

RN 865298-81-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX
NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:1205598 CAPLUS
 DOCUMENT NUMBER: 145:505478
 TITLE: Preparation of tricyclic naphthyridine derivatives, as HIV integrase inhibitors
 INVENTOR(S): Vacca, Joseph P.; Wai, John S.; Payne, Linda S.; Isaacs, Richard C. A.; Han, Wei; Egbertson, Melissa; Pracitto, Richard
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 122pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006121831	A2	20061116	WO 2006-US17369	20060505
WO 2006121831	A3	20071025		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2006244424	A1	20061116	AU 2006-244424	20060505
CA 2607151	A1	20061116	CA 2006-2607151	20060505
EP 1881825	A2	20080130	EP 2006-759135	20060505
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008540529	T	20081120	JP 2008-511195	20060505
US 20090054399	A1	20090226	US 2007-920032	20071107
PRIORITY APPLN. INFO.:			US 2005-679431P	P 20050510
			WO 2006-US17369	W 20060505
OTHER SOURCE(S):	MARPAT 145:505478			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Tricyclic compds. I [R1 = (un)substituted alkyl; R2 = H, alkyl; R3 = H, halo, CN, halo/alkyl, SO₂NH₂ and derivs., NH₂ and derivs., etc.; when R2 and R3 are attached to a double bond, then R2C:CR3 = (un)substituted Ph, 5- to 6-membered heteroaryl; A = (un)substituted 5- to 9-membered saturated or mono-unsatd. heterocyclyl containing 2-4 heteroatoms selected from N, O, S, in which each S is optionally oxidized to SO or SO₂; ; and their pharmaceutically acceptable salts] were prepared as HIV integrase and HIV replication inhibitors. For example, diazocinonaphthyridine II was prepared by coupling acid III (preparation given) with N-[2-(benzyloxy)ethyl]-4-[(tert-butyldimethylsilyl)oxy]butan-1-amine (preparation given), removal of tert-butyldimethylsilyl group, treatment of the alc. with methanesulfonic anhydride, cyclization in the presence of CsCO₃,

and deprotection in the presence of HBr in AcOH (no data for the first two steps). I displayed IC₅₀'s <1 μM in an HIV integrase assay. Pyrazinopyrimidines I exhibited IC₉₅'s of <10 μM for the inhibition of acute HIV infection of T-lymphoid cells. I exhibited no cytotoxicity at concns. ≤10 μM. I are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. I can be employed in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

IT 865300-53-4P, Methyl 6-(3-chloro-4-fluorobenzyl)-3,4-dihydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphthyridine-1-carboxylate
 915065-29-1P, Methyl 2-(4-chlorobutyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate
 915065-30-4P, Methyl 6-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate 915065-31-5P,
 6-(3-Chloro-4-fluorobenzyl)-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylic acid hydrochloride
 915065-36-0P, Methyl 2-(2-tert-butoxy-2-oxoethyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate 915065-66-6P, Methyl
 2-(allyl)-6-(3-chloro-4-fluorobenzyl)-4-hydroxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxylate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of tricyclic naphthyridines as HIV integrase inhibitors)


RN 865300-53-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid,
 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, methyl ester (CA INDEX NAME)




RN 915065-29-1 CAPLUS


CN 2,6-Naphthyridine-1-carboxylic acid,
 2-(4-chlorobutyl)-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, methyl ester (CA INDEX NAME)



RN 915065-30-4 CAPLUS
 CN 2,6-Naphthyridine-1-carboxylic acid,
 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo-, methyl ester (CA INDEX NAME)




RN 915065-31-5 CAPLUS
 CN 2,6-Naphthyridine-1-carboxylic acid,
 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-[4-(methylamino)butyl]-3,5-dioxo-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 915065-36-0 CAPLUS
 CN 2,6-Naphthyridine-2(3H)-acetic acid,
 6-[(3-chloro-4-fluorophenyl)methyl]-5,6,7,8-tetrahydro-4-hydroxy-1-(methoxycarbonyl)-3,5-dioxo-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 915065-66-6 CAPLUS
 CN 2,6-Naphthyridine-1-carboxylic acid,
 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-2-(2-propen-1-yl)-, methyl ester (CA INDEX NAME)



L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1066462 CAPLUS

DOCUMENT NUMBER: 145:419116

TITLE: Preparation of crystalline
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-2-isopropyl-N,N-
dimethyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-
naphthyridine-1-carboxamide sodium salt as an HIV
integrase inhibitor.

INVENTOR(S): Matty, Louis, Jr.; Wang, Yaling

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 23pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006107478	A2	20061012	WO 2006-US7716	20060303
WO 2006107478	A3	20070712		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2005-659952P P 20050309

OTHER SOURCE(S): CASREACT 145:419116

AB Title compound (I) having a specified X-ray powder diffraction pattern was prepared as an HIV integrase inhibitor useful for the prophylaxis or treatment of HIV infection or for the prophylaxis, treatment or delay in the onset of AIDS (no data). I was prepared from Et
6-(3-chloro-4-fluorobenzyl)-4-hydroxy-5-oxo-5,6,7,8-tetrahydro-2,6-
naphthyridine-1-carboxylate in 7 steps.

IT 865300-19-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of crystalline

(chlorofluorobenzyl)hydroxyisopropylidioxohexahydronap


hthyridinedimethylamide sodium salt as an HIV integrase inhibitor)

RN 865300-19-2 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-,
sodium salt (1:1) (CA INDEX NAME)



IT 865298-83-5P 865300-62-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of crystalline
 (chlorofluorobenzyl)hydroxyisopropyldioxohexahydronap
 hthyridinedimethylamide sodium salt as an HIV integrase inhibitor)
 RN 865298-83-5 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-
 (CA INDEX NAME)



RN 865300-62-5 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)



L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1026950 CAPLUS

DOCUMENT NUMBER: 143:326344

TITLE: Preparation of hydroxynaphththyridinediones as HIV integrase inhibitors

INVENTOR(S): Han, Wei; Egbertson, Melissa; Wai, John S.; Zhuang, Linghang; Ruzek, Rowena D.; Perlow, Debra S.; Isaacs, Richard C. A.; Cameron, Mark; Foster, Bruce S.; Dolling, Ulf H.; Hoerrner, R. Scott; Obligado, Vanessa E.; Neilson, Lou Anne; Kim, Boyoung; Payne, Linda S.; Morrisette, Matthew M.; Williams, Peter D.; Pye, Philip J.; Angelaud, Remy; Mancheno, Danny E.; Askin, David

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 193 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087768	A1	20050922	WO 2005-US7772	20050309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005222391	A1	20050922	AU 2005-222391	20050309
CA 2558026	A1	20050922	CA 2005-2558026	20050309
EP 1725556	A1	20061129	EP 2005-725120	20050309
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1930160	A	20070314	CN 2005-80007404	20050309
JP 2007528401	T	20071011	JP 2007-502960	20050309
US 20070179196	A1	20070802	US 2006-587682	20060728
IN 2006DN04787	A	20070831	IN 2006-DN4787	20060821
PRIORITY APPLN. INFO.:			US 2004-551625P	P 20040309
			US 2004-633134P	P 20041203
			WO 2005-US7772	W 20050309
OTHER SOURCE(S):			CASREACT 143:326344; MARPAT 143:326344	
GI				



AB The title compds. I [X1, X2 = H, alkyl, OH, etc.; or X1 and X2 can together form methylenedioxy or ethylenedioxy (if located on adjacent carbons in the Ph ring); X3 = H, alkyl, alkoxy, haloalkyl, haloalkoxy, halo; R4 = alkyl, (un)substituted cycloalkyl, heteroaryl, etc.; R5 = H, alkyl, cycloalkyl, etc.] which are inhibitors of HIV integrase and inhibitors of HIV replication, and therefore are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS, were prepared E.g., a multi-step synthesis of II, starting from piperidin-2-one and 4-fluorobenzyl bromide, was given. The representative compds. I (including II) were tested in the integrase assay and were found to have IC₅₀'s less than about 1 μ M. The compds. I can be employed against HIV infection and AIDS as compds. per se or in the form of pharmaceutically acceptable salts. The compds. I and their salts can be employed as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.


IT 865300-19-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)


RN 865300-19-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-, sodium salt (1:1) (CA INDEX NAME)




● Na


IT 865298-58-4P 865298-70-0P 865298-71-1P
 865300-11-4P 865300-12-5P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)
 RN 865298-58-4 CAPLUS
 CN 2,6-Naphthyridine-1-carboxylic acid,
 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-,
 methyl ester (CA INDEX NAME)



RN 865298-70-0 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-
 hexahydro-4-hydroxy-2-methyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-71-1 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-
 hexahydro-4-hydroxy-2-methyl-3,5-dioxo-N-(2,2,2-trifluoroethyl)- (CA
 INDEX NAME)




RN 865300-11-4 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 5-bromo-2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)



RN 865300-12-5 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy- (CA INDEX NAME)



IT 865298-59-5P 865298-60-8P 865298-61-9P
 865298-62-0P 865298-63-1P 865298-64-2P
 865298-65-3P 865298-66-4P 865298-67-5P
 865298-68-6P 865298-69-7P 865298-72-2P
 865298-73-3P 865298-74-4P 865298-75-5P
 865298-76-6P 865298-77-7P 865298-78-8P
 865298-79-9P 865298-80-2P 865298-81-3P
 865298-82-4P 865298-83-5P 865298-84-6P
 865298-85-7P 865298-86-8P 865298-87-9P
 865298-88-0P 865298-89-1P 865298-90-4P
 865298-91-5P 865298-92-6P 865298-93-7P
 865298-94-8P 865298-95-9P 865298-96-0P
 865298-97-1P 865298-98-2P 865298-99-3P
 865299-00-9P 865299-01-0P 865299-02-1P
 865299-03-2P 865299-04-3P 865299-05-4P
 865299-06-5P 865299-07-6P 865299-08-7P
 865299-09-8P 865299-10-1P 865299-11-2P
 865299-12-3P 865299-15-6P 865299-16-7P


865299-17-8P 865299-18-9P 865299-19-0P
 865299-20-3P 865299-22-5P 865299-24-7P
 865299-25-8P 865299-26-9P 865299-27-0P
 865299-28-1P 865299-29-2P 865299-30-5P
 865299-31-6P 865299-32-7P 865299-33-8P
 865299-34-9P 865299-35-0P 865299-36-1P
 865299-37-2P 865299-38-3P 865299-39-4P
 865299-40-7P 865299-41-8P 865299-42-9P
 865299-43-0P 865299-44-1P 865299-45-2P
 865299-47-4P 865299-48-5P 865299-49-6P
 865299-50-9P 865299-51-0P 865299-52-1P
 865299-53-2P 865299-54-3P 865299-56-5P
 865299-57-6P 865299-58-7P 865299-59-8P
 865299-60-1P 865299-61-2P 865299-62-3P
 865299-63-4P 865299-64-5P 865299-65-6P
 865299-66-7P 865299-67-8P 865299-68-9P
 865299-69-0P 865299-70-3P 865299-71-4P
 865299-72-5P 865299-73-6P 865299-74-7P
 865299-75-8P 865299-76-9P 865299-77-0P
 865299-78-1P 865299-79-2P 865299-80-5P
 865299-81-6P 865299-82-7P 865299-83-8P
 865299-84-9P 865299-85-0P 865299-86-1P
 865299-87-2P 865299-88-3P 865299-89-4P
 865299-90-7P 865299-91-8P 865299-92-9P
 865299-93-0P 865299-94-1P 865299-95-2P
 865299-96-3P 865299-97-4P 865299-98-5P
 865299-99-6P 865300-00-1P 865300-01-2P
 865300-02-3P 865300-03-4P 865300-04-5P
 865300-05-6P 865300-06-7P 865300-07-8P
 865300-08-9P 865300-09-0P 865300-10-3P
 865300-13-6P 865300-14-7P 865300-15-8P
 865300-16-9P 865300-17-0P 865300-18-1P
 865300-98-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)


RN 865298-59-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-
 hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-60-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclobutyl-6-[(4-fluorophenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865298-61-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclopropyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865298-62-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-63-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-64-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid,
6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA
INDEX NAME)




RN 865298-65-3 CAPLUS

CN Methanesulfonamide, N-[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-
hydroxy-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865298-66-4 CAPLUS

CN Acetamide, N-[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-
methyl-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865298-67-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-68-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclobutyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-69-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclopropyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-72-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-N-[2-(methylsulfonyl)ethyl]-3,5-dioxo- (CA INDEX NAME)




RN 865298-73-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N,6-bis[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-74-4 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(1-piperidinylcarbonyl)- (CA INDEX NAME)




RN 865298-75-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-(2,2-dimethylpropyl)-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-76-6 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(4-thiomorpholinylcarbonyl)- (CA INDEX NAME)



RN 865298-77-7 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-piperazinylcarbonyl)- (CA INDEX NAME)



RN 865298-78-8 CAPLUS
 CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-piperazinylcarbonyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865298-77-7
 CMF C20 H21 F N4 O4




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 865298-79-9 CAPLUS
 CN 1-Piperazinesulfonamide, 4-[[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-1-yl]carbonyl]-N,N-dimethyl- (CA INDEX NAME)




RN 865298-80-2 CAPLUS

CN 1-Piperazineacetamide, 4-[[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-1-yl]carbonyl]-N,N-dimethyl- α -oxo- (CA INDEX NAME)




RN 865298-81-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865298-82-4 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo-, sodium salt
(1:1) (CA INDEX NAME)



● Na


RN 865298-83-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-
(CA INDEX NAME)




RN 865298-84-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(2-methylpropyl)-3,5-dioxo-
(CA INDEX NAME)




RN 865298-85-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-2-(2-methylpropyl)-3,5-dioxo-
(CA INDEX NAME)




RN 865298-86-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N,N-
diethyl-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX
NAME)



RN 865298-87-9 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-
tetrahydro-8-hydroxy-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (CA
INDEX NAME)



RN 865298-88-0 CAPLUS
 CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865298-87-9
 CMF C22 H24 Cl F N4 O4




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 865298-89-1 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(4-thiomorpholinylcarbonyl)- (CA INDEX NAME)




RN 865298-90-4 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(1-piperidinylcarbonyl)- (CA INDEX NAME)




RN 865298-91-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-(cyclopropylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-92-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-cyclopropyl-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-93-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-ethyl-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-94-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-95-9 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-[(4,4-difluoro-1-piperidiny)carbonyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 865298-96-0 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(4-morpholinylcarbonyl)- (CA INDEX NAME)




RN 865298-97-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865298-98-2 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-[(4-cyclopropyl-1-piperazinyl)carbonyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-
(CA INDEX NAME)




RN 865298-99-3 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-[(4-cyclopropyl-1-piperazinyl)carbonyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 865298-98-2


CMF C24 H26 Cl F N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 865299-00-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N,N-diethyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-01-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-[2-(dimethylamino)ethyl]-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-02-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-N-(1-methyl-4-piperidiny)-3,5-dioxo- (CA INDEX NAME)




RN 865299-03-2 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, N,6-bis[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-04-3 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, N,N-diethyl-6-[(4-fluorophenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865299-05-4 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-
 hexahydro-4-hydroxy-N-methyl-N-(2-methylpropyl)-3,5-dioxo- (CA INDEX
 NAME)



RN 865299-06-5 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, N-ethyl-6-[(4-fluorophenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-07-6 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-
 hexahydro-4-hydroxy-N-methyl-3,5-dioxo-N-propyl- (CA INDEX NAME)




RN 865299-08-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865299-09-8 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)




RN 865299-10-1 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(4-morpholinylcarbonyl)- (CA INDEX NAME)




RN 865299-11-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo-6-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 865299-12-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-15-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(2-methoxyphenyl)methyl]-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-16-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(3-methoxyphenyl)methyl]-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-17-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-6-[(3-methylphenyl)methyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-18-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,4-dimethylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-19-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2,3-dichlorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX
NAME)




RN 865299-20-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2,4-difluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX
NAME)




RN 865299-22-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-
trimethyl-3,5-dioxo-6-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX
NAME)




RN 865299-24-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-25-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluoro-3-methylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-26-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2-bromo-3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-27-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-6-[(2-methylphenyl)methyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-28-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-29-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-6-[(4-methylphenyl)methyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-30-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-chlorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-31-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(4-methoxyphenyl)methyl]-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-32-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,5-dichlorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-33-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX
NAME)




RN 865299-34-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,5-difluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX
NAME)




RN 865299-35-0 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,5-dimethoxyphenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX
NAME)




RN 865299-36-1 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-methylphenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX
 NAME)



RN 865299-37-2 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-fluoro-4-methylphenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX
 NAME)




RN 865299-38-3 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(2,5-difluorophenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX
 NAME)




RN 865299-39-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-2-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-40-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-chloro-2-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-41-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(5-chloro-2-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-42-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2-fluoro-3-methylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-43-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(5-fluoro-2-methylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-44-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,5-dimethylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-45-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(4-hydroxyphenyl)methyl]-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-47-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluoro-3-methoxyphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-48-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-methoxyphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-49-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-chloro-3-methylphenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-50-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3,4-difluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-51-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(2-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-52-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chlorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-53-2 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2,3,4,6-tetrahydro-8-hydroxy-2-[(4-methoxyphenyl)methyl]-6-methyl-5-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)




RN 865299-54-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(4-methoxyphenyl)methyl]-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-56-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(4-methylphenyl)-3,5-dioxo-
(CA INDEX NAME)




RN 865299-57-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-phenyl- (CA
INDEX NAME)




RN 865299-58-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-(3-thienyl)- (CA
INDEX NAME)




RN 865299-59-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-(3-pyridinyl)- (CA INDEX NAME)




RN 865299-60-1 CAPLUS

CN Benzoic acid, 4-[6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-2(3H)-yl]-, methyl ester (CA INDEX NAME)




RN 865299-61-2 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 2-[4-(aminocarbonyl)phenyl]-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-62-3 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-
 [(methylamino)carbonyl]phenyl]-3,5-dioxo- (CA INDEX NAME)



RN 865299-63-4 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[4-
 [(ethylamino)carbonyl]phenyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-
 3,5-dioxo- (CA INDEX NAME)




RN 865299-64-5 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-[[1-
 methylethyl)amino]carbonyl]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-65-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[4-[(dimethylamino)carbonyl]phenyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-66-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[4-[(diethylamino)carbonyl]phenyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-67-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[3-[(dimethylamino)carbonyl]phenyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-68-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(4-nitrophenyl)-3,5-dioxo- (CA INDEX NAME)




RN 865299-69-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-[4-(acetylamino)phenyl]-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-70-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-[4-(acetilmethylamino)phenyl]-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-71-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-[methyl(2,2,2-trifluoroacetyl)amino]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-72-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-[methyl((methylamino)carbonyl)amino]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-73-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[4-[[(dimethylamino)carbonyl]methylamino]phenyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-74-7 CAPLUS

CN Carbamic acid, [4-[6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-2(3H)-yl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 865299-75-8 CAPLUS

CN Carbamic acid, [4-[6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-2(3H)-yl]phenyl]methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 865299-76-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-[(methylsulfonyl)amino]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-77-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-[methyl(methylsulfonyl)amino]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-78-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-[4-(aminosulfonyl)phenyl]-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-79-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-[(methylamino)sulfonyl]phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-80-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-(4-morpholinylsulfonyl)phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-81-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[4-(methanolsulfonyl)phenyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-82-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(3-cyanophenyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-83-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(4-cyanophenyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-84-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-(4-acetylphenyl)-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-85-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(cyanomethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-86-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(1-cyanoethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-87-2 CAPLUS

CN 2,6-Naphthyridine-2(3H)-acetamide, 6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865299-88-3 CAPLUS

CN 2,6-Naphthyridine-2(3H)-acetamide, 6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-α-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-89-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(cyclopropylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-90-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(cyclobutylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-91-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-(cyclohexylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-92-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-2-(2-methoxyethyl)-N,N-dimethyl-3,5-dioxo-
(CA INDEX NAME)




RN 865299-93-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-(2,2,2-
trifluoroethyl)- (CA INDEX NAME)




RN 865299-94-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-(phenylmethyl)-
(CA INDEX NAME)




RN 865299-95-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-96-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2,6-bis[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-97-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo-2-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 865299-98-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-[2-(4-morpholinyl)ethyl]-3,5-dioxo- (CA INDEX NAME)




RN 865299-99-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 2-(2-aminoethyl)-6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865300-00-1 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865300-01-2 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(2-methylpropyl)-3,5-dioxo- (CA INDEX NAME)



RN 865300-02-3 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(5-chloro-4-fluoro-2-iodophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865300-03-4 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(5-chloro-4-fluoro-2-iodophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(2-methylpropyl)-3,5-dioxo- (CA INDEX NAME)




RN 865300-04-5 CAPLUS

CN Methanesulfonamide, N-[6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865300-05-6 CAPLUS

CN Ethanesulfonamide, N-[6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865300-06-7 CAPLUS

CN Methanesulfonamide, N-[6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-(2-methylpropyl)-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865300-07-8 CAPLUS

CN Methanesulfonamide, N-[6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-(2-methylpropyl)-3,5-dioxo-2,6-naphthyridin-1-yl]-N-ethyl- (CA INDEX NAME)




RN 865300-08-9 CAPLUS

CN Urea, N-[6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo-2,6-naphthyridin-1-yl]-N,N',N'-trimethyl- (CA INDEX NAME)




RN 865300-09-0 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)




RN 865300-10-3 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 5-bromo-2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy- (CA INDEX NAME)




RN 865300-13-6 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)



RN 865300-14-7 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-ethyl-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)



RN 865300-15-8 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-

cyclopropyl-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 865300-16-9 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(3-pyridinyl)- (CA INDEX NAME)




RN 865300-17-0 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(4-pyridinyl)- (CA INDEX NAME)




RN 865300-18-1 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-(2-furanyl)-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 865300-98-7 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6-tetrahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)



IT 865300-88-5 1056715-72-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)
 RN 865300-88-5 CAPLUS
 CN 2,6-Naphthyridine-1-carboxylic acid,
 2,3,5,6,7,8-hexahydro-4-hydroxy-6-[(4-methoxyphenyl)methyl]-2-methyl-3,5-dioxo-, methyl ester (CA INDEX NAME)




RN 1056715-72-0 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo- (CA INDEX NAME)



IT 865300-36-3P 865300-53-4P 865300-54-5P
 865300-62-5P 865300-73-8P 865300-81-8P
 865300-86-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)


RN 865300-36-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid,
6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-,
ethyl ester, sodium salt (1:1) (CA INDEX NAME)




RN 865300-53-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid,
6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-
dioxo-, methyl ester (CA INDEX NAME)




RN 865300-54-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid,
6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-
methyl-3,5-dioxo-, methyl ester (CA INDEX NAME)




RN 865300-62-5 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865300-73-8 CAPLUS
 CN Carbamic acid, [2-[6-[(3-chloro-4-fluorophenyl)methyl]-1-[(dimethylamino)carbonyl]-5,6,7,8-tetrahydro-4-hydroxy-3,5-dioxo-2,6-naphthyridin-2(3H)-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 865300-81-8 CAPLUS
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)



RN 865300-86-3 CAPLUS
 CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT:



6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1026949 CAPLUS
DOCUMENT NUMBER: 143:326343
TITLE: Preparation of hydroxynaphthyridinediones as HIV
integrase inhibitors
INVENTOR(S): Han, Wei; Egbertson, Melissa; Wai, John S.; Zhuang,
Linghang; Ruzek, Rowena D.; Perlow, Debra S.;
Obligado, Vanessa E.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087767	A1	20050922	WO 2005-US7730	20050309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
BR 2005008495	A	20070731	BR 2005-8495	20050309
IN 2006CN03154	A	20070608	IN 2006-CN3154	20060831
MX 2006010252	A	20061030	MX 2006-10252	20060908
PRIORITY APPLN. INFO.:			US 2004-551625P	P 20040309
			US 2004-633134P	P 20041203
			WO 2005-US7730	W 20050309
OTHER SOURCE(S):		MARPAT 143:326343		
GI				



AB The title compds. I [X1 = H, Br, Cl, F, OMe; X2 = H, Br, Cl, F, OMe, alkyl, etc.; R4 = CO2H, C(O)O(alkyl), CONH2, etc.; R5 = H, alkyl, cycloalkyl, etc.] which are inhibitors of HIV integrase and inhibitors of HIV replication, and therefore are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS, were prepared and formulated. E.g., a multi-step synthesis of II, starting from piperidin-2-one and 4-fluorobenzyl bromide, was given. The representative compds. I (including II) were tested in the integrase assay and were found to have IC50's less than about 1 μ M. The compds. I can be employed against HIV infection and AIDS as compds. per se or in the form of pharmaceutically acceptable salts. The compds. I and their salts can be employed as ingredients in pharmaceutical compns., optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.


IT 865300-98-7

RL: PRPH (Prophetic)

(Preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)

RN 865300-98-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6-tetrahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)



IT 865300-19-2P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)

RN 865300-19-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-,
sodium salt (1:1) (CA INDEX NAME)



● Na


IT 865298-58-4P 865298-70-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)


RN 865298-58-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid,
6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-,
methyl ester (CA INDEX NAME)



RN 865298-70-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




IT 865298-59-5P 865298-60-8P 865298-61-9P
 865298-62-0P 865298-63-1P 865298-64-2P
 865298-65-3P 865298-66-4P 865298-67-5P
 865298-68-6P 865298-69-7P 865298-74-4P
 865298-76-6P 865298-77-7P 865298-78-8P
 865298-81-3P 865298-82-4P 865298-83-5P
 865298-84-6P 865298-85-7P 865298-86-8P
 865298-87-9P 865298-88-0P 865298-89-1P
 865298-90-4P 865298-91-5P 865298-92-6P
 865298-93-7P 865298-94-8P 865298-95-9P
 865298-96-0P 865298-97-1P 865299-00-9P
 865299-04-3P 865299-05-4P 865299-06-5P
 865299-07-6P 865299-08-7P 865299-09-8P
 865299-10-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)


RN 865298-59-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-
 hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-60-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclobutyl-6-[(4-fluorophenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865298-61-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclopropyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865298-62-0 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-63-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-64-2 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid,
6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA
INDEX NAME)




RN 865298-65-3 CAPLUS

CN Methanesulfonamide, N-[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-
hydroxy-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865298-66-4 CAPLUS

CN Acetamide, N-[6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-
methyl-3,5-dioxo-2,6-naphthyridin-1-yl]-N-methyl- (CA INDEX NAME)




RN 865298-67-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-68-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-cyclobutyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-69-7 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, N-cyclopropyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-74-4 CAPLUS
 CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(1-piperidinylicarbonyl)- (CA INDEX NAME)



RN 865298-76-6 CAPLUS
 CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(4-thiomorpholinylcarbonyl)- (CA INDEX NAME)




RN 865298-77-7 CAPLUS
 CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-piperazinylcarbonyl)- (CA INDEX NAME)



RN 865298-78-8 CAPLUS
 CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-piperazinylcarbonyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865298-77-7
 CMF C20 H21 F N4 O4




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 865298-81-3 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865298-82-4 CAPLUS


CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N,2-trimethyl-3,5-dioxo-, sodium salt
(1:1) (CA INDEX NAME)



● Na


RN 865298-83-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(1-methylethyl)-3,5-dioxo-
(CA INDEX NAME)




RN 865298-84-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-2-(2-methylpropyl)-3,5-dioxo-
(CA INDEX NAME)




RN 865298-85-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-2-(2-methylpropyl)-3,5-dioxo-
(CA INDEX NAME)




RN 865298-86-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N,N-
diethyl-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX
NAME)



RN 865298-87-9 CAPLUS


CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-
tetrahydro-8-hydroxy-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (CA
INDEX NAME)



RN 865298-88-0 CAPLUS
 CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 865298-87-9
 CMF C22 H24 Cl F N4 O4




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 865298-89-1 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(4-thiomorpholinylcarbonyl)- (CA INDEX NAME)




RN 865298-90-4 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(1-piperidinylcarbonyl)- (CA INDEX NAME)




RN 865298-91-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-(cyclopropylmethyl)-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-92-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-cyclopropyl-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-93-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-ethyl-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865298-94-8 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865298-95-9 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-5-[(4,4-difluoro-1-piperidiny)lcarbonyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 865298-96-0 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chloro-4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl-5-(4-morpholinylcarbonyl)- (CA INDEX NAME)




RN 865298-97-1 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N,2-dimethyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-00-9 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N,N-diethyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-04-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N,N-diethyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo- (CA INDEX NAME)




RN 865299-05-4 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-N-(2-methylpropyl)-3,5-dioxo- (CA INDEX NAME)




RN 865299-06-5 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, N-ethyl-6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo- (CA INDEX NAME)




RN 865299-07-6 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-3,5-dioxo-N-propyl- (CA INDEX NAME)




RN 865299-08-7 CAPLUS

CN 2,6-Naphthyridine-1-carboxamide, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-N-methyl-N-(1-methylethyl)-3,5-dioxo- (CA INDEX NAME)




RN 865299-09-8 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(1-pyrrolidinylcarbonyl)- (CA INDEX NAME)



RN 865299-10-1 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(4-fluorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-5-(4-morpholinylcarbonyl)- (CA INDEX NAME)



IT 865300-36-3P 865300-53-4P 865300-54-5P


865300-62-5P 865300-86-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of hydroxynaphthyridinediones as HIV integrase inhibitors)


RN 865300-36-3 CAPLUS

CN 2,6-Naphthyridine-1-carboxylic acid, 6-[(4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-dioxo-, ethyl ester, sodium salt (1:1) (CA INDEX NAME)




● Na


RN 865300-53-4 CAPLUS
 CN 2,6-Naphthyridine-1-carboxylic acid,
 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-
 dioxo-, methyl ester (CA INDEX NAME)




RN 865300-54-5 CAPLUS
 CN 2,6-Naphthyridine-1-carboxylic acid,
 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-2-
 methyl-3,5-dioxo-, methyl ester (CA INDEX NAME)



RN 865300-62-5 CAPLUS
 CN 2,6-Naphthyridine-1-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-
 2,3,5,6,7,8-hexahydro-4-hydroxy-N,N-dimethyl-3,5-dioxo- (CA INDEX NAME)



RN 865300-86-3 CAPLUS
 CN 2,6-Naphthyridine-1-carboxylic acid,
 6-[(3-chloro-4-fluorophenyl)methyl]-2,3,5,6,7,8-hexahydro-4-hydroxy-3,5-
 dioxo-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:158668 CAPLUS

DOCUMENT NUMBER: 142:261561

TITLE: Preparation of pyrido[1,2-a]pyrazine-1,8-dione derivatives as HIV integrase inhibitors

INVENTOR(S): Miyazaki, Susumu; Katoh, Susumu; Adachi, Kaoru; Isoshima, Hirotaka; Kobayashi, Satoru; Matsuzaki, Yuji; Watanabe, Wataru; Yamataka, Kazunobu; Kiyonari, Shinichi; Wamaki, Shuichi

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 355 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016927	A1	20050224	WO 2004-JP11869	20040812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2577239	A1	20050224	CA 2004-2577239	20040812
EP 1544199	A1	20050622	EP 2004-771830	20040812
EP 1544199	B1	20081015		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 3814631	B2	20060830	JP 2005-513209	20040812
AT 411315	T	20081015	AT 2004-771830	20040812
EP 2042502	A1	20090401	EP 2008-166109	20040812
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
ES 2315700	T3	20090401	ES 2004-771830	20040812
US 20050054645	A1	20050310	US 2004-958225	20041005
US 20060052361	A1	20060309	US 2005-255605	20051013
US 7211572	B2	20070501		
JP 2006232849	A	20060907	JP 2006-118260	20060421
US 20080161311	A1	20080703	US 2007-783270	20070406
PRIORITY APPLN. INFO.:			JP 2003-293117	A 20030813
			JP 2004-134896	A 20040428
			EP 2004-771830	A3 20040812
			JP 2005-513209	A3 20040812
			WO 2004-JP11869	W 20040812
			US 2004-958225	B1 20041005
			US 2005-255605	A1 20051013

OTHER SOURCE(S): MARPAT 142:261561

GI



I



II

AB The title compds. I [wherein R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; X = (un)substituted CH2, N=CH, or CH=N; Y1-Y2-Y3 = (un)substituted C=CH-NH, N-CH=N, N-CH=CH, C=N-NH, N-N=CH, etc.; R2 = H, alkyl, arylalkyl, or (un)substituted SO2H] or pharmaceutically acceptable salts thereof are prepared as anti-HIV agents. For example, the compound II•HCl was prepared in a multi-step synthesis. II•HCl inhibited HIV integrase with IC50 of <0.01 μM. Formulations containing I as an active ingredient were also described.


IT 845719-70-2P 845719-85-9P 845720-07-2P
845720-08-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrido[1,2-a]pyrazine-1,8-dione derivs. as HIV integrase inhibitors)


RN 845719-70-2 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3-chlorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 845719-85-9 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2-[(3,4-dichlorophenyl)methyl]-2,3,4,6-tetrahydro-8-hydroxy-6-methyl- (CA INDEX NAME)




RN 845720-07-2 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2,3,4,6-tetrahydro-8-hydroxy-6-methyl-2-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 845720-08-3 CAPLUS

CN 2,6-Naphthyridine-1,7-dione, 2,3,4,6-tetrahydro-8-hydroxy-2-[(3-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)



REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

39.98

226.08

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.74

-5.74

STN INTERNATIONAL LOGOFF AT 15:09:48 ON 04 MAY 2009